NasdaqGM:MIRMBiotechs
A Fresh Look at Mirum Pharmaceuticals (MIRM) Valuation After Strong Q2 Earnings and Raised 2025 Guidance
If you are looking at Mirum Pharmaceuticals (MIRM) right now, you are not alone. The company just delivered a 64% year-over-year jump in revenue and beat expectations on earnings per share for the second quarter of 2025. Management responded by raising their full-year outlook for 2025, a move that usually signals growing confidence in the business. While there was an insider sale and fresh regulatory filings this month, the uptick in performance is what seems to be catching investors’...